Meta Analysis Of Aidi Injection Combined With Gemcitabine And Cisplatin In The Treatment Of Non-small Cell Lung Cancer

Purpose:The safety and efficacy of aidi injection combined with gemcitabine and cisplatin in the treatment of non-small cell lung cancer was meta-analyzed.Material and method:Retrieve CNKI、wangfang,、the Chinese biomedical database(CBM)、 VIP、 Pubmed(MEDLINE)、Embase、 the Cochrane library,etc.for the time from database established by December 2018,keywords for "aidi injection" and"non-small cell lung cancer","GP","gemcitabine and cisplatin,etc.Meta analysis were performed on the included literatures by using the Rev Man5.3 software and Cochrane collaboration system evaluation method.The meta-analysis indicators according to the included literatures were classified as binary data,represented by odds ratio(OR)and 95% confidence interval(95%CI)and continuous data,and represented by weighted mean difference(MD)and its 95% confidence interval(95%CI)。Results:1.A total of 16 modified randomized controlled trials were included,with a total of1357 patients with non-small cell lung cancer.2.The effective rate of aidi injection combined with gemcitabine and Cisplatin in the treatment of non-small cell lung cancer was compared with the control group,and the combined effect volume [OR = 1.55,95%CI(1.25,1.92);P < 0.0001].3.The quality of life of the two groups was compared with the combined effect volume[OR = 2.02,95%CI(1.45,2.83);P <0.00001 ].4.The gastrointestinal reactions of the two groups were compared with the combined effects volume[OR = 0.45,95%CI(0.33,0.60);P <0.00001].5.The reduction of white blood cell level II and above was compared between the two groups with the combined effect volume [OR = 0.37,95%CI(0.23,0.59),P< 0.0001].6.The reduction of platelet level II and above was compared between the two groups with the combined effector volume [OR = 0.57,95% CI(0.34,0.96),P =0.03].7.Comparison of liver function injury between the two groups with the combinedeffects volume[OR = 0.66,95%CI(0.44,0.98),P = 0.05].8.Comparison of renal function injuries between the two groups with the combined effects volume[OR = 0.9,95%CI(0.51,1.57),P = 0.7].9.The immune index CD3+ was compared between the two groups with the combined effects volume[MD =-6.86,95%CI(-8.12,-5.60),P ≤0.00001]。10.The immune index CD8+ was compared between the two groups with the combined effects volume[MD=-17.09,95%CI(-18.33,-15.41),P≤0.00001]。11.The immune index CD4+/ CD8+ was compared between the two groups with the combined effects volume[MD=-0.26,95%CI(-0.34,-0.18),≤0.00001]。Conclusion:Aidi injection combined with GP regimen chemotherapy is more advantageous than simple GP regimen chemotherapy in the treatment of NSCLC solid tumor efficiency,can significantly improve the quality of life of NSCLC patients,reduce the adverse digestive tract reaction in the course of chemotherapy,improve the white blood cells,thrombocytopenia due to GP regimen chemotherapy,improve the immune function of T lymphocytes in NSCLC patients.